Advising on Pharmaceutical Discovery and Development Strategy
As one of the largest and most research-intensive public universities in the nation, The Ohio State University has a breadth of resources. The Ohio State University Comprehensive Cancer Center (OSUCCC) has five highly interactive cancer research programs involving more than 340 scientists from 11 of the 15 colleges at Ohio State.
The Drug Development Institute (DDI) is staffed by scientists with experience in the pharmaceutical industry at all stages of the drug discovery and development process. Our team advises on how a project should be advanced from the earliest stages of discovery to clinical trial phases and beyond.
Our broad areas of expertise include:
- Molecular Biology
- Medicinal and Process Chemistry
- Preclinical and Clinical Pharmacology
- Pharmaceutical Industry Project Management
- Interactive Network of Specialized Drug Development Resources
Directing Preclinical Drug Development Activities
The DDI leverages world-class research and drug development resources at The Ohio State University to advance projects from early drug discovery through preclinical and clinical development. When necessary, the DDI partners with external contract research organizations. The DDI team coordinates and manages all of the necessary early stage drug development activities to ensure a seamless integration of project teams and timely progression of projects.
Managing Intellectual Property
Intellectual property is the tangible, marketable core of every DDI-invested project. Each project has an intellectual property strategy defined before DDI investment. The intellectual property strategy is used to guide the drug development strategy and influences overall pipeline decisions as well. The DDI works closely with licensing officers at the Ohio State Technology Commercialization Office (TCO) to ensure that our invested projects are appropriately disclosed, patented and protected. The DDI and TCO also work together on external partnering, licensing negotiations and contract terms for invested projects.
Developing a Commercialization Strategy
The DDI evaluates the commercial viability of every technology prior to investment and regularly throughout the development process. The DDI recognizes that the pharmaceutical competitive landscape is constantly evolving and that the clinical need for a product may change dramatically within a short time. To understand and respond to changes in commercial potential, the DDI leverages both internal and external resources:
- The DDI works with the Ohio State Fisher College of Business Center for Innovation and Entrepreneurship (CIE) to analyze the commercial potential and market position for every invested drug development project. The CIE is experienced in triaging early-stage technologies and developing commercialization strategies. It also coordinates clinician surveys to provide a perspective on the optimal drug profile and any potential barriers to entry for a particular therapy or intervention.
- The DDI has an advisory board consisting of highly experienced pharmaceutical industry professionals. The board advises on commercial viability or taps into its extensive networks of contacts to provide expert advice when needed.
Partnering and Managing Relationships
The DDI cultivates relationships between internal and external partners, manages alliances and is flexible with the kinds of partnerships and investment models that are developed. Pipeline projects are available for partnering at all stages in the research and development process. The DDI pipeline provides potential partners with innovative de-risked drug candidates with industry-standard data packages and consolidated intellectual property.
The DDI leverages internal and external resources to accelerate projects. Resources include:
- World-renowned researchers working at one of the largest public universities in the nation
- Partnerships with OSUCCC Shared Resources that provide an integrated network of specialized and cost-effective services to facilitate innovative translational science as well as access to state-of-the-art technology and instrumentation
- Other core resources such as assay development, compound profiling and more
- Business analysts at the CIE
- Licensing expertise at the TCO
- Strategic partnerships with recognized experts in the Pharma and compound development industries as well as the government
- Contracted capabilities such as toxicity studies
For more information, contact the DDI at email@example.com.